Australia

Australia National Pathology Standards (First Edition 2027)

91 controls. 5 other frameworks in our corpus share controls with it. Here is all of it, and how much of it you are already doing.

Page built . This page is derived from the framework corpus, which changes when the corpus is extended rather than daily.

91 controls 5 frameworks share controls with it Australia verified against its source document

Every control below is one this framework asks for. The right hand column counts how many other frameworks in our corpus carry the same control, which is the difference between doing this work once and doing it again for the next standard.

There is no implementation kit for this framework yet. The control list and the overlap above are free and complete.

What you already have

Frameworks whose controls overlap this one, most first. If you run any of them, the count is roughly what you have already evidenced.

Every control

CodeControlAlso in
1.01Governance, leadership and culture: the governing body endorses the clinical governance and risk frameworks, puts patient safety and appropriate test use ahead in business and cont1
1.02Designated person: the governing body places delivery of pathology services under the direction and control of an Ahpra-registered medical practitioner residing in Australia with t2
1.03Delegations: operate an authorisation process that delegates responsibility for aspects of the practice only to workforce members with the qualifications and skills for the task wh2
1.04Legislation and standards: comply with applicable Commonwealth, state and territory legislation and regulations, the relevant NPAAC standards and, where no NPAAC standard covers a 1
1.05Contracted services: where the practice subcontracts or coordinates pathology services for other organisations, ensure subcontractors are accredited to the relevant NPAAC standards1
1.06Referral laboratories: ensure Australian referral laboratories are accredited to the relevant NPAAC standards and ISO 15189, prefer accredited international laboratories, communica1
1.07Environmental sustainability: use the governance systems to implement best practice strategies that reduce the practice's environmental impact1
1.08Information governance: implement interoperable health information systems conformant with national digital health standards and legislation, monitor data quality, keep laboratory 1
1.09Artificial intelligence governance: implement an AI management system consistent with relevant international standards such as ISO/IEC 420011
10.01Analytical and clinical performance requirements: document for every area of testing the analytical and clinical performance requirements using key indicators for quantitative anal1
10.02Analytical and clinical performance: ensure analytical performance meets the assay's clinical application, support morphological and interpretive diagnostic performance through pee1
10.03Measurement uncertainty process: for quantitative assays define the measurand, indicate the laboratory's confidence in each measurement, provide information for interpreting result1
10.04Measurement uncertainty use: match the effort spent on uncertainty to the clinical quality requirements, set routine performance goals and reduce uncertainty sources when goals are1
10.05Quality control process: the designated person oversees quality control, every assay has a documented quality control process assessing performance, the process specifies the crite1
10.06Frequency of quality control testing: test control samples at a frequency based on the stability and robustness of the method and the risk of patient harm, and additionally when cr1
10.07Test procedures: align with best practice guidelines, follow the manufacturer's instructions or the practice's validated and authorised variation, maintain specimen integrity throu1
10.08Test results: ensure the workforce determining results are competent, work in optimal conditions with appropriate equipment for interpretation, have evidence-based reference interv1
10.09Disposal of biological material: hold a waste management policy and comply with jurisdictional regulations on the disposal of biological material from pathology testing0
10.10External quality assurance programs: participate in EQA for the preanalytical, analytical and postanalytical phases of every test or test group with an available program, assess pr1
10.11Morphological external quality assurance: ensure every workforce member involved in morphological diagnosis takes part in at least one relevant EQA program a year, retain individua1
10.12Internal quality assurance: where no suitable EQA exists, use alternative internal quality assurance for the preanalytical, analytical and postanalytical phases, addressing high-ri1
11.01Contracted PoCT services: where the practice coordinates point of care testing for a health service, hold an agreement that specifies each party's roles and responsibilities0
11.02PoCT roles and responsibilities: ensure the workforce performing point of care testing are skilled, competent and within scope, can perform, interpret, monitor and produce reliable1
11.03PoCT training: scale training to device complexity, test volume, operator frequency and quality assessment findings; have a qualified person deliver defined training covering at mi1
11.04PoCT performance management: review the performance of workforce members undertaking point of care testing to ensure competence, and identify their training, development and superv0
11.05Interprofessional collaboration: when coordinating point of care testing for health services, provide opportunities for collaboration between the practice's workforce and the clini0
11.06PoCT procedures: in addition to the practice's test procedures, ensure PoCT procedures include traceability of samples to the original specimen, patient and device, include referen1
11.07PoCT test results: ensure results and related information from point of care devices are included in the patient's healthcare record, automatically where possible1
2.01Policies and procedures: establish policies and processes for every laboratory and service, make them readily available to the workforce and support their use, monitor and improve 1
2.02Risk management: establish and operate a risk management system that identifies, reviews and mitigates risks, records safety and quality risks in the risk plan, uses clinical and o1
2.03Ongoing service provision: maintain business continuity plans, reviewed regularly and improved, that keep pathology services running through disruptions, emergencies and disasters0
2.04Adaptable and resilient systems: manage software updates and system changes through a change control process, validate and test changes affecting regulated software before clinical1
2.05Interoperable information systems: use national healthcare identifiers for patients, organisations and providers, apply standard information structures and national terminologies i1
2.06Appropriate care: identify, assess and implement contemporary evidence-based pathology services and technologies that improve clinical care, and identify and reduce pathology servi1
2.07Quality management systems: collect and interpret safety and quality data on specimen collection, integrity, traceability and testing, equipment testing, result interpretation and 1
2.08Incident management: support the workforce to recognise and report incidents and involve them in review, let consumers and requesters raise concerns, nominate investigators with ri1
2.09Open disclosure: use an open disclosure process consistent with the Australian Open Disclosure Framework and monitor and improve its use and effectiveness1
2.10Feedback and complaints management: document feedback and complaints from requesters, patients, families and carers, inform the designated person, escalate and correct where commun1
3.01Supervision requirements: ensure the workforce delegated to supervise pathology tests understand their responsibilities and are trained for them, support requesters with enquiries,1
3.02Supervision framework: document a supervision framework that delegates supervision of every pathology test to supervising medical practitioners within their scope of practice, ensu2
3.03Workforce and supervision risks: record and rate supervision risks from vacancies and extended leave in the risk system, rate skills and supervisory gaps from vacancy or extended l1
3.04Mitigating supervision risks: actively recruit to vacancies and give supervising medical practitioners, clinical scientists and scientists access to training and experience that ma1
4.01GX laboratory designated person: a full-time pathologist appointee who supervises only within scope, delegates supervision of tests outside their scope to pathologists with the rel2
4.02GX laboratory pathologist and clinical scientist supervision: at least one full-time equivalent pathologist with the relevant scope who is onsite in a laboratory 80 percent of the 0
4.03GY and B laboratories are associated with the GX laboratory in the same pathology network, and the GX designated person holds responsibility for their clinical governance0
4.04GY and B laboratories operate under the network supervision framework the designated person developed, with onsite supervising pathologists of appropriate scope providing supervisi1
4.05GY and B laboratories: undertake a documented, ongoing risk assessment of the adequacy of onsite supervision covering test volume, complexity and acuity, workforce composition and 1
4.06GX, GY and B clinical governance: run a common clinical governance system across GX, GY and B laboratories0
4.07GY and B laboratories receive effective virtual supervision through at least monthly meetings with time for safety, quality and operational performance, annual visits by skilled an0
4.08S laboratory: perform a limited range of tests for a target population related to the designated person's qualifications, skills and scope, apply for GX status if wider testing is 1
4.09Complex genomic testing in S laboratories: where an S laboratory performs complex genomic testing, both a genetic pathologist and a clinical scientist with relevant scope supervise0
4.10SB laboratories are associated with an S laboratory in the same pathology network0
4.11Each SB laboratory has full-time supervision and clinical governance from an S laboratory designated person, a supervision framework that person developed, supervising specialist m0
4.12S and SB clinical governance: run a common clinical governance system across S and SB laboratories, give SB laboratories effective virtual supervision through at least monthly meet1
4.13M laboratory: perform a limited range of tests only for patients of the associated medical practice, consistent with the designated person's qualifications, skills and defined scop0
4.14M laboratory test scope: provide tests using IVD medical devices included in the ARTG or otherwise permitted under the therapeutic goods framework, from haematology (excluding immu0
4.15M laboratory designated person: a medical practitioner competent to provide the tests performed, who has completed a training program in the operation, monitoring and use of the in2
4.16M laboratory supervision framework: delegations clearly set out who holds authority for pathology tests during operational hours0
4.17M laboratory competence: the designated person assesses the skills and competence of the workforce performing pathology tests every year0
5.01Pathology workforce roles and responsibilities: confirm qualifications, knowledge, experience, skills and recency of practice, define functions and responsibilities and support the1
5.02Training to improve the quality of patient care: orient and train the workforce in their safety and quality roles on commencement and when those responsibilities change, provide ac1
5.03Evidence-based care: give the workforce ready access to professional and best practice guidelines, decision-support tools and resources relevant to their practice, and support thei1
6.01Healthcare rights: deliver person-centred care aligned to a charter of rights consistent with the Australian Charter of Healthcare Rights, support the workforce to apply its princi1
6.02Informed consent: ensure consent processes comply with legislation, enable patients to consent to specimen collection and, where required, to testing, give transparent financial in2
6.03Decision-making: at collection centres identify patients who need support to make decisions, give them access to that support and involve supporters and substitute decision-makers 1
6.04Accessing specimen collection services: make information available to patients and carers on the collection services offered, contact details, locations, opening hours, bookings an1
6.05People with diverse care needs: provide a safe environment and deliver person-centred, culturally safe care when collecting specimens and communicating results1
7.01Supporting requesters: advise on available services, request requirements including the clinical information needed, appropriateness, limitations, prerequisites and preparation, co1
7.02Patient identification and service matching: define and approve at least three patient identifiers for the record and primary specimen label, include national health identifiers wh1
7.03Communicating results: use a results system that supports interoperability through SPIA-aligned terminology and structures, addresses report structure and content, delivers accurat1
7.04Reporting critical results: use processes that promptly recognise critical results (preferably automated), interpret and report them in a timely manner across all operational perio2
7.05Healthcare records: collect, store and share patient information and pathology records in line with national and jurisdictional legislation including sharing-by-default requirement1
7.06Notifiable diseases: document and report notifiable diseases to the relevant authorities and disease registries in accordance with jurisdictional requirements0
8.01Medical device implementation and replacement: ensure devices are on the ARTG or, if developed in-house, validated to ISO 15189 and compliant with NPAAC and regulatory requirements1
8.02Medical device use: use devices for their intended purpose per the manufacturer's instructions for use, classify commercial IVDs used outside their intended purpose (such as unspec1
8.03Medical device maintenance: keep a current and complete device inventory, store devices per the manufacturer's instructions, use in-date reagents and consumables per the instructio1
8.04In-house IVD medical devices: validate clinical and analytical performance, comply with TGA requirements for in-house IVDs, assess against the NPAAC in-house IVD requirements, demo1
8.05Adverse medical device events: report adverse events involving commercial and in-house IVD medical devices to the TGA within the specified timeframes, in the required format and in0
8.06IVD software and AI governance and implementation: ensure commercial IVD software is on the ARTG and in-house IVD software including diagnostic AI is managed as an in-house IVD und1
8.07IVD software and AI clinical use and oversight: use IVD software and AI only for their intended purpose and with evidence of clinical benefit or improved accuracy, efficiency or de1
9.01Specimen collection environment: comply with regulations and jurisdictional requirements, design, maintain and equip facilities to support safe care, provide fit-for-purpose and we1
9.02Infection prevention and control in collection centres: keep a clean, safe and hygienic environment consistent with the national infection control guidelines and state or territory1
9.03Recognising acute deterioration and escalating care: implement processes to respond promptly when a patient's physical or cognitive state deteriorates acutely, have referral pathwa1
9.04Request assessment: perform services only on a documented request naming the patient, requesting practitioner and services, assess Medicare-funded requests for compliance with the 1
9.05Specimen collection processes: describe each service, its purpose, the standard collection procedure, temperature-controlled storage needs and maximum storage time; keep processes 1
9.06Optimising specimen collection: keep consumables available, in date and easy to find and use, have the collection workforce maintain specimen integrity through correct preparation,1
9.07Specimen storage: provide dedicated, suitable and secure storage at the required temperature, follow and document safety, stability and security requirements for specimens retained1
9.08High acuity settings and critical requests: ensure high acuity settings know who collects and transports specimens, use evidence-based approaches so testing occurs within the clini1
BackgroundBackground: the Commission administers the National Pathology Accreditation Scheme, NPAAC formulates the standards, NATA assesses conformity, and the Approval Principles under the 0
GlossaryGlossary: the defined terms the actions rely on, including designated person, clinical scientist, supervising medical practitioner, critical results, high acuity setting, critical 0
IntroductionIntroduction and application: a nationally consistent framework that replaces seven NPAAC requirements, read with the Approval Principles, binding on Medicare-funded pathology prac0

Tell me when Australia National Pathology Standards (First Edition 2027) files something new

One email when a public company newly discloses something this framework governs, naming the company and what our corpus says it puts in scope. Nothing else, and one click to stop.

What this page is

A control-level reference for Australia National Pathology Standards (First Edition 2027), drawn from our framework corpus. Control codes and titles are references to the standard, not reproductions of it. The overlap counts and the auditor artefacts are our own work and are the part you will not find elsewhere.

Measure this against what you already run · All frameworks · Today's edition